Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
50% autologous serum eye drops for corneal epithelial injury
RBR-34d3jv2Phase 2Recruiting
- Sponsor
- Federal University of São Paulo
- Start
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous serum artificial tears in keratitis, dry eye syndrome (DED) and neurotrophic keratitis (NK), sponsored by Federal University of São Paulo. Started Sep 2023; status: recruiting.
02
Drugs
autologous serum artificial tears
03
Conditions
keratitisdry eye syndrome (DED)neurotrophic keratitis (NK)
Beyond the preview
Go deeper on RBR-34d3jv2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-34d3jv2.